PL1899459T3 - Otrzymywanie komórek Tr1 specyficznych wobec antygenu pokarmowego lub autoantygenu z populacji leukocytów lub PBMC - Google Patents

Otrzymywanie komórek Tr1 specyficznych wobec antygenu pokarmowego lub autoantygenu z populacji leukocytów lub PBMC

Info

Publication number
PL1899459T3
PL1899459T3 PL06808973.9T PL06808973T PL1899459T3 PL 1899459 T3 PL1899459 T3 PL 1899459T3 PL 06808973 T PL06808973 T PL 06808973T PL 1899459 T3 PL1899459 T3 PL 1899459T3
Authority
PL
Poland
Prior art keywords
leukocyte
antigen
population
food
pbmc
Prior art date
Application number
PL06808973.9T
Other languages
English (en)
Inventor
Françoise Cottrez
Hervé Groux
Valérie Brun
Arnaud Foussat
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of PL1899459T3 publication Critical patent/PL1899459T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/45—Bacterial antigens
    • A61K40/4524—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/45—Bacterial antigens
    • A61K40/453—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C12N2500/95—Protein-free medium and culture conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/53—CD2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/50—Coculture with; Conditioned medium produced by invertebrate cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
PL06808973.9T 2005-07-01 2006-07-03 Otrzymywanie komórek Tr1 specyficznych wobec antygenu pokarmowego lub autoantygenu z populacji leukocytów lub PBMC PL1899459T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05291429A EP1739166B1 (en) 2005-07-01 2005-07-01 Obtention of food- or auto-antigen specific Tr1 cells from a leukocyte or PBMC population

Publications (1)

Publication Number Publication Date
PL1899459T3 true PL1899459T3 (pl) 2016-10-31

Family

ID=36168439

Family Applications (2)

Application Number Title Priority Date Filing Date
PL05291429T PL1739166T3 (pl) 2005-07-01 2005-07-01 Otrzymywanie komórek Tr1 specyficznych wobec antygenu pokarmowego lub autoantygenu z populacji leukocytów lub PBMC
PL06808973.9T PL1899459T3 (pl) 2005-07-01 2006-07-03 Otrzymywanie komórek Tr1 specyficznych wobec antygenu pokarmowego lub autoantygenu z populacji leukocytów lub PBMC

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL05291429T PL1739166T3 (pl) 2005-07-01 2005-07-01 Otrzymywanie komórek Tr1 specyficznych wobec antygenu pokarmowego lub autoantygenu z populacji leukocytów lub PBMC

Country Status (14)

Country Link
US (1) US7977093B2 (pl)
EP (2) EP1739166B1 (pl)
JP (2) JP5502322B2 (pl)
AT (1) ATE513903T1 (pl)
AU (1) AU2006271320B2 (pl)
CA (1) CA2613778C (pl)
CY (2) CY1112351T1 (pl)
DK (2) DK1739166T3 (pl)
ES (2) ES2368152T3 (pl)
HU (1) HUE029143T2 (pl)
PL (2) PL1739166T3 (pl)
PT (2) PT1739166E (pl)
SI (2) SI1739166T1 (pl)
WO (1) WO2007010406A2 (pl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA015989B1 (ru) 2005-08-31 2012-01-30 АйТиЭйч ИММЬЮН ТЕРАПИ ХОЛДИНГЗ АБ Лечение воспалительного заболевания кишечника
ES2595103T3 (es) 2007-10-17 2016-12-27 Txcell Células Tr1, células madre mesenquimales y usos de estas
EP2050814A1 (en) * 2007-10-17 2009-04-22 Txcell Compositions for treating multiple sclerosis
EP2062970A1 (en) * 2007-11-26 2009-05-27 Txcell Compositions for treating an intestinal inflammatory condition
DK2113254T3 (da) 2008-04-28 2012-12-03 Txcell Sammensætninger til behandling af en inflammatorisk autoimmun sygdom
EP2113560A1 (en) * 2008-04-28 2009-11-04 TXCell Compositions for treating an arthritic condition
PL2318020T3 (pl) * 2008-06-30 2016-02-29 Univ Heidelberg Immunosupresyjne komórki krwi i sposób ich wytwarzania
GB0820397D0 (en) * 2008-11-07 2008-12-17 Cellerix Sa Cells, nucleic acid constructs, cells comprising said constructs and methods utilizing said cells in the treatment of diseases
EP2221364A1 (en) * 2009-02-23 2010-08-25 TXCell Compositions for treating an allergic or asthmatic condition
BR112013023968A2 (pt) 2011-03-25 2016-12-13 Txcell uso de células t reguladoras para a fabricação de medicamentos para tratar condição inflamatória ou autoimune
EP2982746A1 (en) 2014-08-07 2016-02-10 TXCell Regulatory T cells with therapeutic potential
KR101697473B1 (ko) 2014-11-26 2017-01-18 주식회사 녹십자랩셀 T 세포를 이용한 자연살해세포의 배양방법
EP3633029A4 (en) 2017-05-26 2021-06-09 Green Cross Lab Cell Corporation METHOD OF DEVELOPING A NATURAL KILLER CELL USING A T-CELL
TWI832820B (zh) * 2017-07-21 2024-02-21 美商伯克利之光生命科技公司 抗原呈現合成表面、共價功能化表面、經活化之t細胞及其用途
AU2019215034C1 (en) 2018-02-01 2022-01-06 Nkmax Co., Ltd. Method of producing natural killer cells and composition for treating cancer
KR102232321B1 (ko) * 2018-03-23 2021-03-26 주식회사 녹십자랩셀 자연살해세포의 제조방법
US12343397B2 (en) 2018-05-17 2025-07-01 Regents Of The University Of Minnesota Drug-resistant immune cells and methods of use thereof
MY199770A (en) 2018-11-14 2023-11-22 Green Cross Lab Cell Corp Method for culturing cord blood-derived natural killer cells using transformed t cells
PL238336B1 (pl) * 2019-08-22 2021-08-09 Gdanski Univ Medyczny Sposób otrzymywania in vitro antygenowo-specyficznych limfocytów T regulatorowych

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0814838B1 (en) * 1995-03-08 2003-05-14 The Scripps Research Institute Antigen presenting system and activation of t-cells
US6670146B2 (en) * 2000-10-04 2003-12-30 Schering Corporation Regulatory T cells; methods
FR2824567B1 (fr) * 2001-05-11 2003-08-08 Inst Nat Sante Rech Med Procede d'obtention de lymphocytes tr1 regulateurs specifiques d'antigene
FR2856700B1 (fr) 2003-06-24 2007-06-08 Txcell Procede d'identification de lymphocytes tr1 regulateurs par la presence et la surexpression de molecules specifiques et ses applications
EP1712615A1 (en) * 2005-04-15 2006-10-18 Txcell In vitro production of a cell population using feeder cells

Also Published As

Publication number Publication date
US7977093B2 (en) 2011-07-12
WO2007010406A3 (en) 2007-03-29
JP2013240334A (ja) 2013-12-05
CY1117772T1 (el) 2017-05-17
WO2007010406A2 (en) 2007-01-25
PL1739166T3 (pl) 2012-01-31
DK1739166T3 (da) 2011-10-10
JP5502322B2 (ja) 2014-05-28
EP1899459A2 (en) 2008-03-19
PT1739166E (pt) 2011-09-22
EP1899459B1 (en) 2016-03-23
AU2006271320A1 (en) 2007-01-25
EP1739166A1 (en) 2007-01-03
AU2006271320B2 (en) 2012-04-26
CA2613778C (en) 2016-06-07
CY1112351T1 (el) 2015-12-09
CA2613778A1 (en) 2007-01-25
DK1899459T3 (en) 2016-07-18
US20090075372A1 (en) 2009-03-19
EP1739166B1 (en) 2011-06-22
JP2008544760A (ja) 2008-12-11
SI1899459T1 (sl) 2016-09-30
SI1739166T1 (sl) 2011-11-30
PT1899459T (pt) 2016-07-08
HUE029143T2 (hu) 2017-02-28
ES2578259T3 (es) 2016-07-22
ATE513903T1 (de) 2011-07-15
ES2368152T3 (es) 2011-11-14

Similar Documents

Publication Publication Date Title
PL1739166T3 (pl) Otrzymywanie komórek Tr1 specyficznych wobec antygenu pokarmowego lub autoantygenu z populacji leukocytów lub PBMC
Lexberg et al. Th memory for interleukin‐17 expression is stable in vivo
Battaglia et al. Tr1 cells: from discovery to their clinical application
IL250313B (en) Expansion of renewable stem cell populations
MY180750A (en) Expansion of lymphocytes with a cytokine composition for active cellular immunotherapy
RU2008129788A (ru) Улучшенный способ увеличения числа опухоле-реактивных т-лимфоцитов в иммунотерапии онкологических больных
ATE459652T1 (de) Verfahren zur herstellung von antikörpern
SG151246A1 (en) Tissue system with undifferentiated stem cells derived from corneal limbus
NO20033396L (no) Forbedret in vitro fremgangsmåte for dyrking av mammale celler for autologcelle implantasjon/transplantasjon fremgangsmåter
BR0311360A (pt) métodos para expansão e transdiferenciação in vitro de células acinares pancreáticas humanas em células produtoras de insulina
WO2007051038A3 (en) Pdx1-expressing dorsal and ventral foregut endoderm
MX2021005480A (es) Metodos para aislar y expandir celulas.
IL218447A0 (en) Co-culture lymphoid tissue equivalent (lte) for an artificial immune system (ais)
ES2132068T3 (es) Factor inhibidor de la sintesis de la citoquina y metodos para usarlo.
WO2004015070A3 (en) Isolation and identification of t cells
Sun et al. Unique roles of Schistosoma japonicum protein Sj16 to induce IFN‐γ and IL‐10 producing CD4+ CD25+ regulatory T cells in vitro and in vivo
WO2006108882A8 (en) In vitro production of a cell population using feeder cells
EP1664280A4 (en) SKIN REGENERATION SYSTEM
MX2021005481A (es) Metodos para aislar y expandir celulas.
WO2006026746A3 (en) Methods to separate and expand antigen-specific t cells
WO2001094551A3 (de) Gen-modifizierte t-zellen, verfahren zu ihrer herstellung und ihre verwendung
CY1107952T1 (el) Δενδριτικα κυτταρα ενεργοποιημενα εν τη παρουσια γλυκοκορτικοειδων ορμονων ειναι ικανα να καταστελλουν αντιγονο-ειδικες αποκρισεις κυτταρων
Moore et al. Dendritic cells and B cells cooperate in the generation of CD4+ CD25+ FOXP3+ allogeneic T cells
AR128988A1 (es) MÉTODO PARA EXPANDIR CÉLULAS T gd
WO2006124827A3 (en) Molecular dissection of cellular responses to alloantigen or autoantigen in graft rejection and autoimmune disease